glp-1 drugs for parkinson's disease Beyond insulin: The Intriguing role of in Further support for GLP-1R agonists

Looking for a specific answer

doi: 10.1016/j.conb.2007.04.010 35

Research published in neuroscience journals has shown that administration of exenatide, liraglutide, and semaglutide decreases alcohol consumption in alcohol-preferring rats and mice, with effects observed across various experimental paradigms including two-bottle choice tests and operant self-administration models

Weight loss, heart protection, kidney protection and more recently brain protectionand of course, anti-ageing - the long (and growing list) of benefits of the drugs pumped out by Danish Pharma, Novo Nordisk and US Pharma, Lilly

[DOI] [PMC free article] [PubMed] [Google Scholar] 53

This is the minimum timeframe established by clinical trial protocols for safe dose escalation